1. Home
  2. OCS vs TECX Comparison

OCS vs TECX Comparison

Compare OCS & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oculis Holding AG Ordinary shares

OCS

Oculis Holding AG Ordinary shares

N/A

Current Price

$7.50

Market Cap

417.3M

Sector

Health Care

ML Signal

N/A

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

N/A

Current Price

$21.06

Market Cap

413.3M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
OCS
TECX
Founded
2003
2019
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
417.3M
413.3M
IPO Year
2022
2018

Fundamental Metrics

Financial Performance
Metric
OCS
TECX
Price
$7.50
$21.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
10
Target Price
$35.89
★ $71.00
AVG Volume (30 Days)
★ 253.1K
157.3K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 40.70
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$389.20
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.78
$16.77
52 Week High
$34.48
$39.53

Technical Indicators

Market Signals
Indicator
OCS
TECX
Relative Strength Index (RSI) 40.30 47.23
Support Level $6.95 $20.52
Resistance Level $8.84 $22.95
Average True Range (ATR) 0.65 1.31
MACD 0.06 0.24
Stochastic Oscillator 33.83 57.68

Price Performance

Historical Comparison
OCS
TECX

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: